Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "minister"

976 News Found

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients
Drug Approval | February 21, 2026

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy


BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences
News | February 19, 2026

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences

40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions


Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
Drug Approval | February 19, 2026

Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg

Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension


European Commission greenlights higher-dose Wegovy for obese adults
News | February 18, 2026

European Commission greenlights higher-dose Wegovy for obese adults

Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose


Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff
News | February 17, 2026

Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff

Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem


Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer
Clinical Trials | February 17, 2026

Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer

The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease


Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
Clinical Trials | February 17, 2026

Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment

Alto met its enrollment goal with 83 patients across 13 US clinical sites


BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
Biopharma | February 16, 2026

BridgeBio reports breakthrough results in Phase 3 achondroplasia trial

Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone


BioAsia 2026 positions Telangana as a global TechBio powerhouse
News | February 14, 2026

BioAsia 2026 positions Telangana as a global TechBio powerhouse

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem